Short Interest in Gelteq Limited Drops 26.3% in March

Hedge fund takes new stake in the biotech company's stock

Mar. 31, 2026 at 4:18am

Got story updates? Submit your updates here. ›

Gelteq Limited (NASDAQ:GELS), a New York-based biotechnology company focused on ingestible gel delivery solutions, saw a significant 26.3% decline in short interest on its stock during March. As of March 13, short interest totaled 100,277 shares, down from 136,088 shares at the end of February.

Why it matters

Fluctuations in short interest can provide insights into investor sentiment and market expectations around a company's performance. The drop in short interest for Gelteq may signal growing confidence in the firm's prospects among some investors.

The details

Gelteq's stock price has traded in a range between $0.64 and $4.11 over the past year. In the most recent quarter, a hedge fund, Susquehanna International Group LLP, established a new position in Gelteq, acquiring 41,550 shares valued at approximately $57,000.

  • As of March 13, 2026, short interest in Gelteq totaled 100,277 shares.
  • On February 26, 2026, short interest in Gelteq was 136,088 shares.

The players

Gelteq Limited

A biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel platforms for nutrient and drug delivery.

Susquehanna International Group LLP

A hedge fund that recently established a new position in Gelteq, acquiring 41,550 shares.

Got photos? Submit your photos here. ›

The takeaway

The decline in short interest for Gelteq suggests that some investors are becoming more optimistic about the company's prospects, potentially signaling confidence in its ingestible gel delivery technology and its ability to commercialize solutions across various industries.